Promore Pharma AB (publ), a biopharmaceutical company, develops therapeutic peptides for the bio-active wound care market in Sweden and internationally. More Details
+ 1 more risk
Adequate balance sheet and overvalued.
Share Price & News
How has Promore Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PROMO is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: PROMO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
7 Day Return
1 Year Return
Return vs Industry: PROMO underperformed the Swedish Biotechs industry which returned 14.9% over the past year.
Return vs Market: PROMO underperformed the Swedish Market which returned 61.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Promore Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
10 months ago | Simply Wall StDid Changing Sentiment Drive Promore Pharma's (STO:PROMO) Share Price Down A Worrying 63%?
1 year ago | Simply Wall StWe Think Promore Pharma (STO:PROMO) Can Afford To Drive Business Growth
1 year ago | Simply Wall StDid Changing Sentiment Drive Promore Pharma's (STO:PROMO) Share Price Down A Worrying 60%?
Is Promore Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PROMO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PROMO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PROMO is unprofitable, so we can't compare its PE Ratio to the SE Biotechs industry average.
PE vs Market: PROMO is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PROMO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PROMO is good value based on its PB Ratio (4.6x) compared to the SE Biotechs industry average (5x).
How is Promore Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Promore Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Promore Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PROMO is currently unprofitable.
Growing Profit Margin: PROMO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PROMO is unprofitable, and losses have increased over the past 5 years at a rate of 34.6% per year.
Accelerating Growth: Unable to compare PROMO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PROMO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1.9%).
Return on Equity
High ROE: PROMO has a negative Return on Equity (-129.03%), as it is currently unprofitable.
How is Promore Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: PROMO's short term assets (SEK25.2M) exceed its short term liabilities (SEK2.6M).
Long Term Liabilities: PROMO's short term assets (SEK25.2M) exceed its long term liabilities (SEK820.0K).
Debt to Equity History and Analysis
Debt Level: PROMO's debt to equity ratio (3.1%) is considered satisfactory.
Reducing Debt: PROMO's debt to equity ratio has reduced from 16.6% to 3.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PROMO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: PROMO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 39.5% each year
What is Promore Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PROMO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PROMO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PROMO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PROMO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PROMO's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jonas Ekblom (55 yo)
Dr. Jonas Ekblom, Ph.D. has been Director at CombiGene AB (publ) since 2020. Dr. Ekblom has been the Chief Executive Officer of Pergamum AB since November 1, 2010 and serves as its President. Dr. Ekblom se...
Experienced Board: PROMO's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Promore Pharma AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Promore Pharma AB (publ)
- Ticker: PROMO
- Exchange: OM
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr104.367m
- Shares outstanding: 36.43m
- Website: https://www.promorepharma.com
Number of Employees
- Promore Pharma AB (publ)
- Karolinska Institutet Science Park
- Fogdevreten 2
- Stockholm County
- 171 65
Promore Pharma AB (publ), a biopharmaceutical company, develops therapeutic peptides for the bio-active wound care market in Sweden and internationally. Its product candidates include PXL01 for the prevent...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/18 17:40|
|End of Day Share Price||2021/04/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.